Biosimilar switching not suitable for all patients

The results of a study showed that when antibodies develop in response to the biological treatment Remicade® (infliximab), they also cross-react with the biosimilar of infliximab (CT-P13: Inflectra® or Remsima®). These findings suggest that antibody-positive patients being treated with Remicade should not be switched to treatment with the biosimilar, since these antibodies will interact with the new drug and potentially lead to a loss of response. ,

Leave a Reply

Your email address will not be published. Required fields are marked *